The Maimonides Institute for Biomedical Research Cordova (Imibic) and the Reina Sofía University Hospital they organize for the second year a informative meeting between professionals and patients with Oligodendrogliomaa rare tumor that usually affects the young adult population between 35 and 45 years of age and is very limiting for people who suffer from it.
This is the second time that Imibic hosts this meeting, since last year it was also held on the occasion of the promotion of a collaboration network between the different centers and professionals whose work focuses on this pathology. The research and care work surrounding this tumor has always gone hand in hand with the association of family members and affected people (Astuce Spain), which since its constitution has had the support of the Malaga actor Manuel Bandera. In fact, today he has once again shown his commitment by participating in the opening of the meeting together with the medical director of Imibic, Pablo Perezand the managing director of the hospital, Garcia Valley.
On Oligodendroglioma
Although it is a pathology infrequent (in Córdoba there are between 40 and 50 patients), the aggressiveness of the treatments that it often involves (surgery, radiotherapy, chemotherapy) and the lethality of the same (implies an average life expectancy of 10 years) make necessary visibility and commitment to research in this field. Along these lines, according to the head of the hospital’s Neurosurgery service, Juan Solivera“forums like this seek precisely to share the knowledge that exists and offer accurate information to patients and families, in addition to making this reality visible.”
Organization of the days
The sessions bring together experts from all mornings different Andalusian hospitals and national references like the doctor Juan Sepulveda, from Hospital 12 de Octubre, who will present the results of the Indigo trial. The content is divided into three blocks who will first review the importance of the multidisciplinary approach led by Dr. Juan Solivera, Dr. Maria Luisa Garciafrom the Malaga Biomedical Research Institute and Nanomedicine Platform (Ibima- Bionand Platform), which will focus on Nanotechnology in translational research of brain tumors, and doctor Jesus Martinfrom the Montpellier University Hospital Center (France), which will address the Neurosurgery of emotions.
In a second block, which will be a round table, advances in clinical and translational research will be presented with the participation of the Neurosurgeon from the Reina Sofía hospital, Alvaro Toledanofrom the medical oncologist at the Virgen Macarena Hospital, Teresa Garciathe radiation oncologist at Virgen del Rocío, Elena Monterothe neuroradiologist at the Reina Sofía Hospital, Manuel Ramos, and the anatomopathologist at the Regional Hospital of Málaga, Raquel Muñoz. A patient will also participate in this table, with the aim of learning more practically about the reality of this disease.
Finally, we will address the advances and new opportunities in the management and treatment of these tumors. In this table, the aforementioned results of the Indigo study will be presented, but also the advances in the treatment of epilepsy and the role of vagal stimulation in oligodendroglioma, by doctor Jose Carlos Estevez, from the Reina Sofía University Hospital, Córdoba; as well as advances in the identification of new diagnostic and/or prognostic biomarkers and therapeutic targets in oligodendrogliomas, by doctor Raul M. Luqueresearcher at Imibic and the University of Cordoba